Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10270632 | 0.92 | — | — | |
| SCHEMBL10271161 | 0.89 | L3MBTL1 (0.34) | L3MBTL1PKMGRM5RAB9ALMNA | |
| SCHEMBL10270623 | 0.88 | L3MBTL1 (0.35) | L3MBTL1PKMGRM5RAB9ALMNA | |
| SCHEMBL10270639 | 0.88 | L3MBTL1 (0.34) | L3MBTL1PKMGRM5RAB9ALMNA | |
| SCHEMBL10271000 | 0.88 | L3MBTL1 (0.36) | L3MBTL1PKMGRM5RAB9ALMNA | |
| SCHEMBL10271151 | 0.85 | L3MBTL1 (0.34) | L3MBTL1PKMGRM5 | |
| SCHEMBL10271160 | 0.83 | L3MBTL1 (0.34) | L3MBTL1PKMGRM5RAB9ALMNA | |
| SCHEMBL15771466 | 0.83 | L3MBTL1 (0.32) | L3MBTL1PKM | |
| SCHEMBL10271150 | 0.82 | L3MBTL1 (0.34) | L3MBTL1PKMGRM5RAB9ALMNA | |
| SCHEMBL15783252 | 0.82 | L3MBTL1 (0.36) | L3MBTL1PKMGRM5RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2012013754-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | PRDX4, PRDX6, DDT | L3MBTL1 773/4885PKM 1289/4885GRM5 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.